The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea
Open accessAbstract
OBJECTIVE: To evaluate the efficacy and safety of canagliflozin, a sodium glucose cotransporter 2 inhibitor, compared with sitagliptin in subjects with type 2 diabetes inadequately controlled with metformin plus sulfonylurea. RESEARCH DESIGN AND METHODS: In this 52-week, randomized, double-blind, active-controlled, phase 3 study, subjects using stable metformin plus sulfonylurea (N = 755) received canagliflozin 300 mg or sitagliptin 100 mg daily. Primary end point was change from baseline in A1C at 52 weeks. Secondary end points included change in fasting plasma glucose (FPG) and systolic blood pressure (BP), and percent change in body weight, triglycerides, and HDL cholesterol. Safety was assessed based on adverse event (AE) reports. RESULTS: At 52 weeks, canagliflozin 300 mg demonstrated noninferiority and, in a subsequent assessment, showed superiority to sitagliptin 100 mg in reducing A1C (−1.03% [−11.3 mmol/mol] and −0.66% [−7.2 mmol/mol], respectively; least squares mean difference between groups, −0.37% [95% CI, −0.50 to −0.25] or −4.0 mmol/mol [−5.5 to −2.7]). Greater reductions in FPG, body weight, and systolic BP were observed with canagliflozin versus sitagliptin (P < 0.001). Overall AE rates were similar with canagliflozin (76.7%) and sitagliptin (77.5%); incidence of serious AEs and AE-related discontinuations was low for both groups. Higher incidences of genital mycotic infections and osmotic diuresis–related AEs were observed with canagliflozin, which led to one discontinuation. Hypoglycemia rates were similar in both groups. CONCLUSIONS: Findings suggest that canagliflozin may be a new therapeutic tool providing better improvement in glycemic control and body weight reduction than sitagliptin, but with increased genital infections in subjects with type 2 diabetes using metformin plus sulfonylurea.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Basevi, V., Di Mario, S., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,055
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“, liraglutide, exenatide) without gastrointestinal symptoms or insulin without weight gain or frequent hypoglycemia (beyond that expected from improved glycemic control) (29,34).”
BackgroundSelf-citationon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Nauck, M. A., Meininger, G., Sheng, D., Terranella, L., Stein, P. P., & Sitagliptin Study 024 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00704.x · Cited by 667
Self-citationStenlöf, K., Cefalu, W. T., Kim, K. ‐., Alba, M., Usiskin, K., Tong, C., Canovatchel, W., & Meininger, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12054 · Cited by 614
Self-citationHermansen, K., Kipnes, M., Luo, E., Fanurik, D., Khatami, H., Stein, P., & Sitagliptin Study 035 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00744.x · Cited by 525
Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., & for the Dapagliflozin 006 Study Group* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00003 · Cited by 467
Rosenstock, J., Aggarwal, N., Polidori, D., Zhao, Y., Arbit, D., Usiskin, K., Capuano, G., Canovatchel, W., & for the Canagliflozin DIA 2001 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1926 · Cited by 421
Self-citationStrojek, K., Yoon, K. H., Hruba, V., Elze, M., Langkilde, A. M., & Parikh, S. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01434.x · Cited by 406
Nomura, S., Sakamaki, S., Hongu, M., Kawanishi, E., Koga, Y., Sakamoto, T., Yamamoto, Y., Ueta, K., Kimata, H., Nakayama, K., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100332n · Cited by 385
Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications
Bakris, G. L., Fonseca, V. A., Sharma, K., & Wright, E. M. (2009) · Kidney International · doi:10.1038/ki.2009.87 · Cited by 358
Sha, S., Devineni, D., Ghosh, A., Polidori, D., Chien, S., Wexler, D., Shalayda, K., Demarest, K., & Rothenberg, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01406.x · Cited by 297
Gastric bypass and banding equally improve insulin sensitivity and β cell function
Bradley, D., Conte, C., Mittendorfer, B., Eagon, J. C., Varela, J. E., Fabbrini, E., Gastaldelli, A., Chambers, K. T., Su, X., Okunade, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64895 · Cited by 244
Liang, Y., Arakawa, K., Ueta, K., Matsushita, Y., Kuriyama, C., Martin, T., Du, F., Liu, Y., Xu, J., Conway, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030555 · Cited by 240
Devineni, D., Morrow, L., Hompesch, M., Skee, D., Vandebosch, A., Murphy, J., Ways, K., & Schwartz, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01558.x · Cited by 220
Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy
Bloomgarden, Z. T., Dodis, R., Viscoli, C. M., Holmboe, E. S., & Inzucchi, S. E. (2006) · Diabetes Care · doi:10.2337/dc06-1120 · Cited by 219
SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
Jurczak, M. J., Lee, H.-Y., Birkenfeld, A. L., Jornayvaz, F. R., Frederick, D. W., Pongratz, R. L., Zhao, X., Moeckel, G. W., Samuel, V. T., Whaley, J. M., et al. (2011) · Diabetes · doi:10.2337/db10-1328 · Cited by 219
Cook, M. N., Girman, C. J., Stein, P. P., & Alexander, C. M. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02078.x · Cited by 197
Cook, M. N., Girman, C. J., Stein, P. P., Alexander, C. M., & Holman, R. R. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.995 · Cited by 187
Neumiller, J. J., White, J. R., & Campbell, R. K. (2010) · Drugs · doi:10.2165/11318680-000000000-00000 · Cited by 156
Gross, J. L., Kramer, C. K., Leitão, C. B., Hawkins, N., Viana, L. V., Schaan, B. D., Pinto, L. C., Rodrigues, T. C., Azevedo, M. J., & for the Diabetes and Endocrinology Meta-analysis Group (DEMA)* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-10-201105170-00007 · Cited by 151
Self-citationMacDonald, F., Peel, J. E., Jones, H. B., Mayers, R. M., Westgate, L., Whaley, J. M., & Poucher, S. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01291.x · Cited by 84
Loopstra, R., Haffner, S. M., Lorenzo, C., Wagenknecht, L. E., & Hanley, A. J. (2011) · Diabetologia · doi:10.1007/s00125-011-2322-2 · Cited by 74
Clinical Approaches to Preserve β-Cell Function in Diabetes
WAJCHENBERG, B. L. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_23 · Cited by 38
Kahleová, H., Mari, A., Nofrate, V., Matoulek, M., Kazdová, L., Hill, M., & Pelikánová, T. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.05.003 · Cited by 38
Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-Ay mice
Katsuno, K., Fujimori, Y., Ishikawa-Takemura, Y., & Isaji, M. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.07.001 · Cited by 35
Yasuda, K., Okamoto, Y., Nunoi, K., et al. (2002) · Hormone and Metabolic Research · doi:10.1055/s-2002-26714 · Cited by 14
Leiter, L. A., Cefalu, W. T., NISKANEN, L. K., et al. (2012) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2012.07.055 · Cited by 13
Cited by
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 694
Metadata
- Authors
- Schernthaner, G., Gross, J. L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., Kawaguchi, M., Canovatchel, W., & Meininger, G.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-08-13
- Volume
- 36
- Issue
- 9
- Pages
- 2508-2515
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2038270027
- Cited by
- 480
- References
- 33
- FWCI
- 62.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.